Jim Cramer gives Johnson & Johnson his stamp of approval

Jim Cramer gives Johnson & Johnson his stamp of approval


Jim Cramer gives Johnson & Johnson his stamp of approval

CNBC’s Jim Cramer on Tuesday advised investors to pick up shares of Johnson & Johnson as a long-term play.

“I like the way J&J’s been trading over the last couple months, and after the quarter we saw this morning I think it is precisely the kind of stock that you need to buy as we head into 2023, which should be a much better year,” he said.

Johnson & Johnson beat top- and bottom-line expectations in its third-quarter results reported before the opening bell on Tuesday. The company lowered its earnings outlook due to the impact of the strong U.S. dollar.

Shares of the company closed down 0.35% after seesawing throughout the trading session — which means there’s now an opportunity for investors to pick up some shares, according to Cramer.

“J&J is a textbook recession-proof stock. … It’s exactly the kind of name you want to own when the Federal Reserve decides to slam the brakes on the economy,” he said.

He did acknowledge that the strong dollar and cost inflation remain serious macroeconomic headwinds to the company. However, those issues will likely become less prominent over the course of 2023, he said, noting that commodity costs have already come down.

Adding to his bull case for Johnson & Johnson is the company’s spinoff of its consumer health segment, which is on track for finalization next year. “I’m confident it’s going to be a tremendous catalyst,” he said.

Disclaimer: Cramer’s Charitable Trust owns shares of Johnson & Johnson.

Jim Cramer’s Guide to Investing

Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.



Source

Space startup Varda raises 7 million in funding to make drugs in orbit
Business

Space startup Varda raises $187 million in funding to make drugs in orbit

Pavlo Gonchar | Lightrocket | Getty Images Space startup Varda announced on Thursday that it has raised $187 million in Series C funding, led by venture capital firms Natural Capital and Shrug Capital, to continue advancing drug manufacturing in space. The latest round included participation from Peter Thiel, Lux Capital, Khosla Ventures and Caffeinated Capital. […]

Read More
How family offices are betting on the sports boom from fantasy apps to pickleball courts
Business

How family offices are betting on the sports boom from fantasy apps to pickleball courts

Key Points A third of investment firms of the ultra-rich have invested in sports, according to a new family office survey by BNY Mellon. While billionaire sports-team buyouts get the headlines, family offices are increasingly investing in adjacent assets like live-viewing venues and betting apps. Here’s how the family offices of ultra-rich sports team owners […]

Read More
Delta’s summer travel outlook tops estimates as CEO says high-end demand is holding up
Business

Delta’s summer travel outlook tops estimates as CEO says high-end demand is holding up

A Boeing 767-332(ER) from Delta Air Lines takes off from Barcelona El Prat Airport in Barcelona on Oct. 8, 2024. Joan Valls | Nurphoto | Getty Images Delta Air Lines trimmed its 2025 profit forecast as it deals with lower-than-expected demand this year and the industry manages a glut of flights, but the carrier’s outlook […]

Read More